Synairgen plc (SYGGF)

Market Cap	110.27K
Revenue (ttm)	n/a
Net Income (ttm)	-8.75M
Shares Out	1.10B
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Average Volume	75
Open	0.0141
Previous Close	0.0001
Day's Range	0.0001 - 0.0141
52-Week Range	0.0001 - 0.0727
Beta	0.31
RSI	12.10
Earnings Date	Sep 23, 2025

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 36
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYGGF

Financial Performance

Financial numbers in GBP